Drugs / Ad-TD-nsIL12
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07472790 | Jul 2026 → Apr 2028 expected | malignant glioma | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05717712 | Jan 2023 → Jan 2025 overdue | diffuse intrinsic pontine glioma, virus associated tumor | Capital Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT05717699 | Jan 2023 → Jan 2025 overdue | diffuse intrinsic pontine glioma, virus associated tumor | Capital Medical University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07126990 | Feb 2025 → Aug 2028 expected | glioma | Xiaorong Wu | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad-TD-nsIL12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05717699 ↗ |
| Known as | BioTTT001 | “Novel oncolytic virus Ad-TD-nsIL12（BioTTT001）” NCT07472790 ↗ |
| Route | Other | “Ad-TD-nsIL12 intratumoral injection” NCT05717699 ↗ |